No photo of Victoria Meucci Villaflor

View Scopus Profile

Victoria Meucci Villaflor

  • 1372 Citations
20052023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Training Experience

2001Residency, Rush University Medical Center
2004Fellowship, Rush University Medical Center

Education/Academic qualification

MD, Rush Medical College

… → 1998

Fingerprint Dive into the research topics where Victoria Meucci Villaflor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Esophageal Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Head and Neck Neoplasms Medicine & Life Sciences
Chemoradiotherapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Survival Medicine & Life Sciences
Induction Chemotherapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2017 2023

Prot #Ad-p53-002: A Phase 2, Multi-Center, Open Label Study to Evaluate Efficacy and Safety of Adenoviral p53 (Ad-p53) in Combination with Immune Checkpoint Inhibitor Therapy in Patients with Progression or Recurrence of Head and Neck Squamous Cell Carcin

Villaflor, V. M.

MultiVir Inc.

11/22/19 → 11/22/22

Project: Research project

Prot #BTCRC-HN17-111: Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-Positive Salivary Gland Carcinoma

Villaflor, V. M.

Hoosier Cancer Research Network, Inc., Merck Sharp & Dohme Corp.

10/9/19 → 10/9/22

Project: Research project

Prot #WO40242: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-PD-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of Th

Villaflor, V. M.

Genentech, Inc.

8/21/19 → 8/21/22

Project: Research project

Prot #HCRN GI17-319/NU UNC19I02: A Single Arm, Multi-Center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-Line, Metastatic, HER2-Amplified Gastric and Esophageal Adenocarcinomas

Villaflor, V. M.

Hoosier Cancer Research Network, Inc., EMD Serono Research & Development Institute, Inc.

8/12/19 → 8/12/22

Project: Research project

Prot #CACZ885U2301: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-Based Doublet Chemotherapy with or without Canakinumab as First Line Therapy for Locally Advanced or Met

Villaflor, V. M.

Novartis Pharmaceuticals Corporation

5/20/19 → 6/1/23

Project: Research project

Research Output 2005 2019

  • 1372 Citations
  • 40 Article
  • 8 Review article
  • 2 Comment/debate
  • 1 Chapter
7 Citations (Scopus)

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer

Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A., Mohindra, N. A., Villaflor, V. M. & Giles, F., Mar 1 2019, In : Clinical Lung Cancer. 20, 2, p. 88-96.e6

Research output: Contribution to journal › Article

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA Repair
Ligands
Mutation

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer

Chae, Y. K., Viveiros, P., Lopes, G., Sukhadia, B., Sheikh, M. M., Saravia, D., Florou, V., Sokol, E. S., Frampton, G. M., Chalmers, Z. R., Ali, S. M., Ross, J. S., Chang, S., Wang, S., Chiec, L., Rahbari, A., Mohindra, N., Villaflor, V., Shin, S. H., Oh, M. & 5 others, Anker, J., Park, L. C., Wang, V., Chuang, J. & Park, W., Oct 2019, In : Journal of Thoracic Oncology. 14, 10, p. 1807-1817 11 p.

Research output: Contribution to journal › Article

Frameshift Mutation
Lung Neoplasms
Tumor Burden
Atlases
Renal Cell Carcinoma
4 Citations (Scopus)

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer

Chae, Y. K., Davis, A. A., Agte, S., Pan, A., Simon, N. I., Iams, W. T., Cruz, M. R., Tamragouri, K., Rhee, K., Mohindra, N. A., Villaflor, V. M., Park, W., Lopes, G. & Giles, F. J., Jun 1 2019, In : Oncologist. 24, 6, p. 820-828 9 p.

Research output: Contribution to journal › Article

Tumor Burden
Non-Small Cell Lung Carcinoma
DNA
Neoplasms
Programmed Cell Death 1 Receptor

Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522)

Seiwert, T. Y., Foster, C. C., Blair, E. A., Karrison, T. G., Agrawal, N., Melotek, J. M., Portugal, L., Brisson, R. J., Dekker, A., Kochanny, S., Gooi, Z., Lingen, M. W., Villaflor, V. M., Ginat, D. T., Haraf, D. J. & Vokes, E. E., Oct 1 2019, In : Annals of Oncology. 30, 10, 1 p.

Research output: Contribution to journal › Comment/debate

Open Access
Oropharyngeal Neoplasms
12 Citations (Scopus)

Optima: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

Seiwert, T. Y., Foster, C. C., Blair, E. A., Karrison, T. G., Agrawal, N., Melotek, J. M., Portugal, L., Brisson, R. J., Dekker, A., Kochanny, S., Gooi, Z., Lingen, M. W., Villaflor, V. M., Ginat, D. T., Haraf, D. J. & Vokes, E. E., Feb 1 2019, In : Annals of Oncology. 30, 2, p. 297-302 6 p.

Research output: Contribution to journal › Article

Oropharyngeal Neoplasms
Chemoradiotherapy
Radiotherapy
Induction Chemotherapy
Clinical Trials